The European Congress on Obesity wrapped this week in Istanbul, and Novo Nordisk presented a dataset that genuinely expanded semaglutide’s clinical profile in a direction most pharmacists weren’t watching. This is not another weight loss efficacy story. It is a neurological and psychiatric protection story, and it came from over 34,000 real women.
What the ECO 2026 Data Actually Showed
At the European Congress on Obesity 2026 in Istanbul, Novo Nordisk announced data from three separate investigations: the STEP UP clinical weight management trial, the landmark SELECT cardiovascular trial, and one large-scale real-world evidence study. The findings were presented May 12, 2026.
The headline that stopped the congress:
In a real-world study of more than 34,000 menopausal women in the United States who took hormone therapy, Wegovy, or a combination of both, women taking Wegovy had an average 42 to 45% lower risk of migraine starting six months after initiation, and a 25% lower risk of depression, compared with menopausal hormone therapy alone.
These are not marginal signal findings from a small trial. They come from a one-year real-world cohort of 34,000 women, in a population that carries enormous and historically undertreated burdens of both migraine and depression.
The cardiovascular data added a third dimension. In a post-hoc analysis of the SELECT trial, perimenopausal and postmenopausal women with obesity and established heart disease experienced meaningful risk reductions in major adverse cardiovascular events, including a 42% relative risk reduction in perimenopausal women specifically. The results were numerically larger than in the overall SELECT population, suggesting that the perimenopausal window may be a particularly impactful period to initiate therapy.
STEP UP analyses of the higher 7.2 mg semaglutide dose showed that 84% of weight loss was derived from fat mass, with preserved muscle function and improved intramuscular fat as a cardiometabolic marker. Nearly half of women in all menopausal stage groups shifted from obesity categories to the overweight or normal weight range by week 72.
Why Migraine Worsens During Perimenopause And Why This Data Matters
To understand why semaglutide’s migraine effect is clinically significant, you need to understand what happens neurologically during perimenopause.
The frequency of migraine attacks is higher in women during perimenopause and postmenopause than in premenopause. Estrogen doesn’t decline steadily during the transition. It swings erratically, and every dip is a potential trigger. Declining estrogen levels are the primary driver of increased headache frequency during the menopausal transition. Hot flashes and insomnia interrupt sleep and lower migraine threshold. Heavy menstrual bleeding triggers prostaglandin release and iron deficiency, both of which worsen attacks.
Around 30% of women see migraine peak during perimenopause, with attacks that tend to be more severe, longer, and harder to treat than before. A 2025 population study following nearly 5,000 women found that 46% continued having migraine attacks after menopause, and 1 in 5 was still having attacks after age 60.
Obesity amplifies all of this. The chronic release of inflammatory mediators and substance P from adipose tissue, and the persistent activation of the trigeminal system from CGRP, which is highly expressed in obese individuals, create a vicious cycle of pain in menopausal women who gain weight. These mechanisms directly connect weight control to migraine burden in this population.
This is the biological context that makes the 42 to 45% migraine risk reduction so meaningful. Semaglutide doesn’t just reduce weight in menopausal women. It reduces the inflammatory and neurological burden that drives migraine frequency in exactly the years when those attacks are most severe and most resistant to standard prevention.
The Depression Signal and What Drives It
The 25% reduction in depression risk deserves equal attention, because the mechanism is distinct from the migraine pathway.
Estrogen fluctuations during the menopausal transition are a recognized risk factor for depressive disorders. Perimenopausal women face significant hormonal instability, combined with sleep disruption, hot flashes, changes in body composition, and the psychological dimensions of the transition. These factors collectively elevate depression and anxiety rates in ways that often go unaddressed by standard care.
GLP-1 receptors are expressed in the brain, including limbic and reward circuits that regulate mood, as covered in an earlier issue of this newsletter in the context of alcohol use disorder. The neuropsychiatric effects of semaglutide observed in the menopausal population likely reflect this central mechanism in addition to weight-mediated metabolic improvements.
The clinical implication: a perimenopausal patient whose depression began or worsened with the hormonal transition, who is also managing obesity, may be a candidate for semaglutide whose full therapeutic benefit extends well beyond the scale.
How This Changes Your Counseling Conversation
Most pharmacists currently frame Wegovy conversations around two questions: How much weight will I lose? And will my insurance cover it?
This ECO 2026 data adds three more dimensions to that conversation for female patients in the perimenopausal and postmenopausal window.
The studies show that when women with obesity lose weight with semaglutide, they improve body composition with reduced visceral fat, reduce their risk of heart attacks and strokes, and improve quality of life outcomes from migraine burden to depression and menopause symptoms.
That is a women’s health conversation, not a weight management conversation.
The perimenopausal woman currently taking sumatriptan for monthly migraines and escitalopram for depression, who is also on Wegovy for obesity, may be experiencing benefits from semaglutide that no provider has ever connected for her. The pharmacist who makes that connection builds a clinical relationship that no chain pharmacy or mail-order service can replicate.
Your Clinical Action This Week
Review the GLP-1 patients in your panel who are women between 40 and 60. Identify those who are also on migraine medications, antidepressants, or cardiovascular preventive therapies.
Those patients deserve a specific conversation. The structure is simple: “New data from a major obesity congress this week shows semaglutide may reduce migraine frequency by over 40% and depression risk by 25% in women your age. Have you noticed any changes in those areas since starting therapy?”
That question has three immediate clinical functions. It gives the patient information about the drug they’re already taking that no one has shared with her. It opens a door to discussing whether her migraine or antidepressant burden has changed since initiating therapy. And it creates the opportunity to document and report a real-world benefit that adds to the evidence base.
If the patient is on hormone therapy and has not yet started a GLP-1, the new data changes the clinical conversation in the other direction. The combination arm of the real-world study produced the most favorable migraine and depression outcomes. A conversation about adding semaglutide to existing MHT in a patient with obesity, migraines, and depression now has direct supporting evidence from a 34,000-patient cohort.
The Data Limitations to Acknowledge
This newsletter covers this data because it is clinically significant. It also requires appropriate framing.
The migraine and depression findings come from an observational real-world study, not a randomized controlled trial. Confounding is possible. The SELECT and STEP UP data are from randomized controlled trials, but the menopausal stage subgroup analyses are post-hoc, meaning they were not the primary endpoint. This is hypothesis-generating data that should change the clinical conversation, not replace randomized evidence.
What it does change, right now, is the breadth of clinical benefit a pharmacist should discuss with female patients at or approaching menopause who are candidates for or already taking semaglutide. The drug a patient is taking for obesity may also be working on her migraines, her depression, and her cardiovascular risk simultaneously. She deserves to know that.
Sources: Novo Nordisk Press Release / Investegate (ECO 2026 Data Announcement, May 12, 2026), Drug Topics (New Data Show Semaglutide’s Effects on Depression and Migraine, May 2026), The Pharmacist UK (Weight-Loss Jabs Reduce Depression and Migraines in Menopausal Women, May 2026), Medical Update Online (ECO 2026 Full Data Summary), Hospitals Magazine (ECO 2026 Data Coverage), NeurologyLive (Migraines Worsen During Menopausal Transition), Cerebral Torque (Migraine, Menopause, and Hormonal Health, March 2026), PMC / Neurology and Therapy (Menopause, Perimenopause, and Migraine: Understanding the Intersections, 2025), PMC / Menopause (Evaluation and Management of Migraine in Midlife Women), Association of Migraine Disorders (Migraine During Perimenopause and Menopause)